Amoy Diagnostics Co Ltd
SZSE:300685
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
15.78
27.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Amoy Diagnostics Co Ltd
Amoy Diagnostics Co Ltd
Other Current Liabilities
Amoy Diagnostics Co Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Amoy Diagnostics Co Ltd
SZSE:300685
|
Other Current Liabilities
¥75.3m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Other Current Liabilities
¥1.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Other Current Liabilities
¥1.8B
|
CAGR 3-Years
38%
|
CAGR 5-Years
74%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Other Current Liabilities
¥1.9B
|
CAGR 3-Years
53%
|
CAGR 5-Years
54%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Other Current Liabilities
¥2.5B
|
CAGR 3-Years
23%
|
CAGR 5-Years
55%
|
CAGR 10-Years
58%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Other Current Liabilities
¥121.8m
|
CAGR 3-Years
33%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
Amoy Diagnostics Co Ltd
Glance View
Amoy Diagnostics Co., Ltd., nestled in the bustling city of Xiamen, China, has carved out a niche in the world of molecular diagnostics. Founded in 2008, the company has quickly become a pioneer in precision medicine, focusing on the development and commercialization of technologies for the detection of genetic mutations. At the heart of its operation lies its proprietary ADx-ARMS technology, an innovative method allowing for the precise and sensitive detection of mutations in tumor tissues and blood, facilitating oncology diagnostics. This technology not only empowers oncologists with critical insights for tailored cancer treatments but underscores Amoy Diagnostics' commitment to transforming patient care through cutting-edge genetic testing. The commercial prowess of Amoy Diagnostics is, however, much more than its technological innovations. The company thrives on a robust business model that hinges on a symbiotic relationship with the pharmaceutical industry and healthcare providers. By offering diagnostic services and research kits, Amoy Diagnostics provides crucial support in the development of targeted therapies, enabling pharmaceutical companies to test and bring to market personalized medicine solutions. Their revenue stream is bolstered by strategic partnerships and licensing agreements, which allow them to expand their portfolio and market reach both domestically and internationally. This dynamic approach not only ensures a wide adoption of their diagnostic solutions but also firmly positions Amoy Diagnostics as a key player in the rapidly growing field of precision oncology.
See Also
What is Amoy Diagnostics Co Ltd's Other Current Liabilities?
Other Current Liabilities
75.3m
CNY
Based on the financial report for Sep 30, 2024, Amoy Diagnostics Co Ltd's Other Current Liabilities amounts to 75.3m CNY.
What is Amoy Diagnostics Co Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 5Y
-5%
Over the last year, the Other Current Liabilities growth was 230%. The average annual Other Current Liabilities growth rates for Amoy Diagnostics Co Ltd have been 9% over the past three years , -5% over the past five years .
You don't have any saved screeners yet
